Submitting a New Drug Application (NDA) or Biologics License Application (BLA) is a defining milestone but for many sponsors, it’s also one of the most complex. Tight timelines, shifting data, and cross-functional dependencies can quickly lead to confusion and rework.

This Executive Briefing distills insights from an MMS-led expert webinar, sharing proven strategies that have helped sponsors complete over 50 successful submissions in the past five years with zero refusals to file in nearly 20 years.

Whether you’re preparing for your first NDA/BLA or refining your global submission process, this guide offers a clear, actionable roadmap to move forward with clarity and control.

Streamline Your NDA/BLA Submission Process with Proven Best Practices

Download your eBook today ↓

What You’ll Learn

• Adopt a Phased Approach: Break your submission into four manageable stages from planning to IR response for better control and reduced risk.
• Integrate Publishing Early: Learn why aligning publishing strategy from day one improves efficiency and minimizes last-minute bottlenecks.
• Overcome Common Challenges: Anticipate first-time sponsor pitfalls and maintain alignment across teams and vendors.
• Engage Regulators Proactively: Discover how early FDA and global health authority interactions can accelerate success.
• Stay Focused on the Critical Path: Identify key deliverables like ISS/ISE and labeling documents that can impact overall timelines.

Why Download This Briefing?

• Based on real-world experience from MMS experts who’ve led global submissions with zero refusals to file.
• Offers a structured framework adaptable for any sponsor size or therapy area.
• Provides checklists and actionable steps to strengthen submission readiness and cross-team collaboration.